Taken in conjunction with similar pharmacodynamic changes in plasma Tie2, induced by cediranib in patients diagnosed with glioma [57], these findings together suggest that plasma Tie2 is the first tumour vascular response biomarker for VEGF inhibitors [58]. Here, TEK is linked to glioma.